InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,732.93
(
0.25%
)
US TECH 100
19,338.80
(
-0.39%
)
Dow Jones
42,208.22
(
0.20%
)
Brent Oil
74.64
(
0.10%
)
Bitcoin
63,822.27
(
-0.69%
)
Post# of 253213
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

north40000

Send PM Follow Ignore
Followers 260
Posts 18197
Boards Moderated 0
Alias Born 01/19/2006

north40000

Member Level

Re: vinmantoo post# 218550

Wednesday, 04/18/2018 1:47:37 PM

Wednesday, April 18, 2018 1:47:37 PM

Post# of 253213
Do you attribute the increased efficacy, OS, of the Keytruda/Pt chemo combination in patients having negative or no PD-L1[TPS=0 for PDL-1] to Keytruda or to the chemo portion of the combination used in therapy?

I gather we still have no data for RRRs in therapy using Keytruda alone, mono-therapy, in NSCLC that exceeds the expected 20-30% in targeted patients having PDL-1. Any side effects, sAEs, of the combination therapy I leave alone for now.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up